The Régie de l’assurance maladie du Québec (RAMQ) issued a notice on March 3, 2021 announcing the end of insurance coverage for Humalog 100 U/ml insulin.
From now on, any new patient covered by the Régie de l’assurance maladie du Québec (RAMQ) who is prescribed insulin lispro 100 U/ml will begin treatment with Admelog®.
Admelog® and Admelog® SoloStar® (Sanofi) are biosimilars to insulin lispro injection, whose reference products are Humalog® and Humalog® KwikPen? Learn more about biosimilar insulins here.
Anyone who started treatment with Humalog 100 U/ml and received reimbursement from the RAMQ or a private insurer before March 3, 2021 will continue treatment with Humalog 100 U/ml until April 13, 2022. After this date, Admelog® insulin will be reimbursed for everyone, with some exceptions.
Please note that the Humalog 200 U/ml formulation (Eli Lilly) is not affected by this new measure.
All the details here.